Načítá se...
Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
The negative regulator of p53, MDM2, is frequently overexpressed in acute myeloid leukemia (AML) that retains wild-type TP53 alleles. Targeting of p53-MDM2 interaction to reactivate p53 function is therefore an attractive therapeutic approach for AML. Here we show that an orally active inhibitor of...
Uloženo v:
| Vydáno v: | Nat Commun |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group UK
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6814808/ https://ncbi.nlm.nih.gov/pubmed/31653912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-12555-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|